IP6 (Inositol 1,2,3,4,5,6-hexakisphosphate) / BioEnh Cancer Research Results

IP6, IP6 (Inositol 1,2,3,4,5,6-hexakisphosphate): Click to Expand ⟱
Features:
Vitamin like substance. Found in cereals, nuts and legumes.
Inositol hexaphosphate (IP6) is a dietary component that constitutes approximately 1 to 5% of the weight of most cereals, nuts, oil seeds, legumes, and grains [1, 2]. In particular, approximately 9.5 to 14.5% of the weight of rice bran is composed of IP6.

IP6 (inositol hexaphosphate) — also called myo-inositol hexakisphosphate, InsP6, phytic acid, or phytate, is a naturally occurring highly phosphorylated inositol carbohydrate abundant in cereal grains, legumes, nuts, seeds, and rice bran and also present at lower concentrations in mammalian cells. It is formally classified as a dietary phytochemical / polyphosphorylated inositol and is marketed as a dietary supplement rather than an approved anticancer drug. Standard abbreviations include IP6 and InsP6. Its unusually high negative charge gives it strong multivalent-cation binding properties, particularly toward iron, zinc, calcium, and magnesium. Experimental anticancer effects are broad but predominantly preclinical, and the extracellular millimolar concentrations commonly used in cancer-cell experiments are far above measured circulating human concentrations.

Primary mechanisms (ranked):

  1. Suppression of PI3K/PDK1/AKT/mTOR survival and growth signaling, including reduced AKT and p70S6K phosphorylation.
  2. Cell-cycle inhibition through ↑ p21 and p27, ↓ cyclin D1/CDK activity, ↓ pRB phosphorylation, and reduced E2F signaling, producing predominantly G1 arrest.
  3. Induction of apoptosis through inhibition of prosurvival AKT signaling, ↑ Bax/Bcl-2 ratio, caspase activation, and PARP cleavage.
  4. Suppression of NF-κB and related inflammatory/prosurvival signaling, including inhibition of IKK/IκB signaling in responsive cancer models.
  5. Anti-invasive and antimetastatic activity through ↓ integrin/focal-adhesion signaling, ↓ MMP expression or secretion, reduced migration and invasion, and in some models suppression of EMT.
  6. Antiangiogenic activity associated with ↓ VEGF, HIF-1α, eNOS, and tumor microvascular markers in preclinical models.
  7. Modulation of MAPK, PKC, RAS/ERK, AP-1, and related growth-regulatory signal-transduction networks in a model-dependent manner.
  8. Promotion of cancer-cell differentiation toward a less malignant phenotype, reported across several experimental tumor systems.
  9. Iron and transition-metal chelation with inhibition of metal-catalyzed hydroxyl-radical generation; this antioxidant mechanism is biologically relevant but is not equivalent to the intracellular cytotoxic mechanisms observed at high experimental IP6 concentrations.
  10. Immune Modulation: – Some studies suggest that IP6 may enhance the immune response against tumors, contributing to its overall anti-cancer activity.

Bioavailability / PK relevance: Oral IP6 is measurably absorbed in humans but systemic exposure is very low. Human studies report basal plasma concentrations around 0.07 mg/L during an IP6-poor diet and approximately 0.26 mg/L during a normal IP6-containing diet, with a plasma maximum occurring roughly 4 hours after an oral dose. IP6 is highly charged, undergoes gastrointestinal interactions with minerals, and can be dephosphorylated to lower inositol phosphates after uptake. Oral exposure therefore does not reproduce the extracellular millimolar concentrations commonly used in cell culture.

In-vitro vs systemic exposure relevance: This is a major translational limitation. Many anticancer experiments use approximately 0.5–5 mM IP6, equivalent to roughly 330–3300 mg/L, whereas measured human plasma IP6 is typically well below 1 mg/L. Thus common in-vitro concentrations exceed measured circulating exposure by roughly three to four orders of magnitude. At millimolar concentrations IP6 also strongly chelates cations and can alter culture-medium chemistry, so some reported effects require cautious interpretation. Tissue uptake, local gastrointestinal exposure, and formation of lower inositol phosphates may nevertheless produce biological effects not predicted solely from plasma IP6 concentration.

Clinical evidence status: Small human / adjunct use; not established anticancer therapy. The strongest cancer evidence remains cell-culture and animal work. Small randomized or prospective breast-cancer studies of IP6 with myo-inositol and/or topical IP6 during chemotherapy have reported better quality-of-life measures and attenuation of some treatment-associated hematologic or local symptoms, but these trials were small and were not adequate demonstrations of improved tumor response, progression-free survival, or overall survival. IP6 has no established regulatory approval for cancer treatment. A separate long-term oral IP6 study in superficial siderosis is registered but remains listed as not yet recruiting and does not establish efficacy. The principal practical safety constraint is mineral chelation: high phytate exposure can reduce iron and zinc absorption, particularly when nutritional status is marginal. Caution is also appropriate with significant iron deficiency and with anticoagulant therapy because antiplatelet effects have been reported.

IP6 Cancer-Relevant Mechanisms

Rank Pathway / Axis Cancer Cells Normal Cells Primary Effect Notes / Interpretation
1 PI3K AKT mTOR survival signaling ↓ PI3K, PDK1, AKT phosphorylation, mTOR signaling, p70S6K ↔ / context-dependent ↓ proliferation and survival; ↑ apoptosis One of the best-supported anticancer axes. Demonstrated in prostate and colon cancer models. In-vitro effects commonly require millimolar IP6.
2 Cell-cycle control ↑ p21; ↑ p27; ↓ cyclin D1; ↓ CDK2/CDK4 activity; ↓ pRB phosphorylation; ↓ E2F ↔ / context-dependent ↑ G1 cell-cycle arrest Strong mechanistic evidence in prostate and other cancer-cell models. Direction of individual regulators can vary by cell type and experimental conditions.
3 Apoptotic machinery ↑ Bax/Bcl-2 ratio; ↑ caspase-3; ↑ caspase-9; ↑ PARP cleavage Generally much less cytotoxic ↑ programmed cancer-cell death Closely coupled to suppression of AKT and other survival signaling.
4 NF-κB inflammatory survival signaling ↓ IKK activity; ↓ IκB phosphorylation; ↓ nuclear NF-κB p50/p65 ↓ inflammatory signaling (context-dependent) ↓ prosurvival and inflammatory transcription Demonstrated particularly in constitutively active prostate-cancer models and stress-induced signaling systems.
5 Migration invasion and extracellular matrix ↓ adhesion; ↓ migration; ↓ invasion; ↓ MMP-2/MMP-3/MMP-9 and related MMP signaling Not well established ↓ metastatic phenotype Breast and colon cancer studies show reduced extracellular-matrix adhesion, motility, invasion, and MMP activity or expression.
6 Integrin and focal-adhesion signaling ↓ α2β1; ↓ α5β1; ↓ αvβ3-related adhesion signaling (model-dependent) Not established ↓ attachment and motility Supports the anti-invasive phenotype but evidence is predominantly older in-vitro work.
7 EMT and epithelial differentiation ↓ EMT; ↑ E-cadherin; ↓ N-cadherin; ↑ claudin-7 in selected IP6 plus inositol models ↔ / not established ↓ metastatic plasticity; ↑ epithelial phenotype Recent colorectal models support EMT suppression, particularly with IP6 plus myo-inositol. Combination findings should not automatically be attributed to IP6 alone.
8 Angiogenesis and hypoxic signaling ↓ VEGF; ↓ HIF-1α; ↓ eNOS; ↓ CD31 Not well established ↓ tumor angiogenesis Supported mainly by prostate xenograft and related preclinical models.
9 RAS MAPK PKC AP-1 signaling ↓ growth-promoting signaling (model-dependent) Context-dependent ↓ proliferation and tumor-promoting transcription IP6 affects several interconnected signaling pathways; individual MAPK components do not show a uniform direction across all experimental systems.
10 Wnt β-catenin signaling ↓ Wnt/β-catenin activity (model-dependent) Not established ↓ proliferation and metastatic progression Supported mainly by colorectal cancer animal studies, including IP6 plus inositol combinations.
11 Cancer-cell differentiation ↑ differentiation; ↓ malignant phenotype Phenotypic normalization Repeatedly reported experimentally, although the precise responsible signaling pathway varies among tumor systems.
12 Transition-metal chelation and oxidative stress ↓ Fe-mediated hydroxyl-radical generation; ROS response variable ↓ oxidative damage Antioxidant and metal-binding activity IP6 strongly complexes iron and other polyvalent cations. ROS should not be assigned a universal ↑ or ↓ direction in cancer cells because redox effects depend heavily on model, dose, metal availability, and extracellular chemistry.
13 Chemosensitization and treatment tolerance ↑ treatment response in some preclinical models ↓ selected chemotherapy-associated toxicity in small human studies Potential adjunctive effect Human evidence is more convincing for supportive-care outcomes than for enhanced tumor control. Combination with myo-inositol is common in clinical reports.
14 Clinical Translation Constraint Experimental activity often requires 0.5–5 mM extracellular IP6 High intake can ↓ iron and zinc bioavailability Limits direct translation of cell-culture anticancer effects Measured human plasma exposure is far below common anticancer cell-culture concentrations. High concentrations can chelate culture-medium metals and alter experimental conditions. Cancer trials are small and have not established tumor-control or survival benefit.


BioEnh, bioenhancer: Click to Expand ⟱
Source:
Type:
A bioenhancer is an agent capable of enhancing bioavailability and efficacy of a drug with which it is co-administered

Query Database for BioEnhancers but the bioenhancers mainly show up under the target notes

Bioenhancers
- piperine and quercetin are considered bio-enhancers
- genistein
Piperine act by suppressing P-gp and cytochrome P450 enzymes, which counteract the metabolism of rifampicin via these proteins, thus enhancing the oral bioavailability of rifampicin. It also decreases the intestinal production of glucuronic acid, thus allowing more substances to enter the body in active form. It was found to increase the bioavailability of various drugs from 30% to 200%.[25]
Table 1: Published research on bioenhancer effect of piperine with various medicines
Drug Studied in Reference
Antimicrobial agents
Rifampicin In vitro Balakrishnan et al, 2001[11]
Isoniazid Rabbits Karan et al, 1998 [12]
Pefl oxacin Mountain Gaddi goats Madhukar et al, 2008[13]
Tetracycline Rats Atal et al, 1980[14]
Sulfadiazine Rats and dogs Atal et al, 1980[14]
Oxytetracycline Poultry birds Singh et al, 2005[15]
Ampicillin Rabbits Janakiraman and Manavalan, 2008[16]
Norfl oxacin Rabbits Janakiraman and Manavalan, 2008 [16]
Nevirapine Adult males Kasibhatta et al, 2007 [17]
Metronidazole In vitro Singh et al, 2010[18]
Analgesics
Diclofenac sodium Albino mice Pooja et al, 2007[19]
Pentazocine Albino mice Pooja et al, 2007[19]
Nimesulide Mice Gupta et al, 1998[20]
Antiepileptics
Carbamazepine In vitro Pattanaik et al, 2009 [21]
Phenytoin Human volunteers Bano et al, 1987[22]
Pentobarbitone Rats Majumdar et al, 1990[23]
Other drugs
Propranolol In vitro Bano et al, 1991 [24]
Theophylline In vitro Bano et al, 1991 [24]
Nutrients In vitro Pooja et al, 2007 [19
***Borneol
-Borneol is thought to temporarily open tight junctions between endothelial cells, enhancing drug penetration. It may also downregulate efflux transporters such as P-glycoprotein (P-gp), allowing higher intracellular concentrations of co-administered drugs.

-presence of urea (as a carrier) increased the aqueous solubility of capsaicin by 3.6-fold compared to pure capsaicin

Quercetin is found in citrus fruits and is a dual inhibitor of cytochrome P 3A4 (CYP3A4) and P-gp.
Table 2: Effect of quercetin pretreatment/co-treatment on pharmacokinetic parameters of different drugs
Drugs combined Increase in pharmacokinetic parametera
Cmax AUC ABA
Verapamil Two fold Two fold SH
Diltiazem SH SH Not known
Paclitaxel SH SH T wo fold
Digoxin 413% 170% Not known
Tamoxifen SH SH 59%
Compared to drug in question alone. Cmax, peak plasma concentration; AUC, area under the curve; ABA, absolute bioavailability; SH, significantly higher.

Another flavonoid, genistein belongs to the isoflavone class of flavonoids. It is a well-known phytoestrogen. The presence of genistein (10 mg/kg) caused an increase in AUC (54.7%) and a decrease in the total plasma clearance (35.2%) after oral administration of paclitaxel at a dose of 30 mg/kg in rats.[37]
Naringin is the major flavonoid glycoside found in grapefruit and makes grapefruit juice taste bitter. Oral naringin (3.3 and 10 mg/kg) was pretreated 30 min before and after intravenous administration of paclitaxel (3 mg/kg), the AUC was significantly improved (40.8% and 49.1% for naringin doses of 3.3 and 10 mg/kg, respectively).[38

Carum carvi/Cuminum cyminum ( Jeera)
Carum carvi seeds are a prized culinary herb. Extracts of its parts increased significantly (25%–300%), the bioavailability of a number of classes of drugs, such as antibiotics, antifungals, antivirals, anticancer, cardiovascular, anti-inflammatory/ antiarthritic, anti-TB, antileprosy, antihistaminic/respiratory disorders, corticosteroids, immunosuppressants, and antiulcers. Such extracts either in the presence or absence of piperine have been found to be highly selective in their bioavailability/bioefficacy-enhancing action.[40]
Capmul
One of the widely used bioenhancers is Capmul MCM C10, a glyceryl monocaprate, produced from edible fats and oils and is commonly used in lip products. In a study in rats, antibiotic ceftriaxone when given concomitantly with capmul, increased the bioavailability of ceftriaxone by 80%.[41]
Nitrile glycoside
Nitrite glycoside is a bioenhancer for drugs and nutrients. Novel bioactive nitrile glycosides, niaziridin and niazirin is obtained from the leaves, pods, and bark of Moringa oleifera. [42] An immunoenhancing polysaccharide and niaziminin, having structural requirement to inhibit tumor promoter-induced Epstein–Barr virus activation have been reported from the leaves of Moringa.[43,44] It enhances the bioactivity of commonly used antibiotics, such as rifampicin, tetracycline, and ampicillin, and also facilitate the absorption of drugs, vitamins, and nutrients through the gastrointestinal membrane, thus increasing their bioavailability. [41] Niazirin is another bioactive nitrile glycoside belonging to M. oleifera. [45,46] Process of isolation of nitrite glycoside from M. oleifera has been patented (US 6858588) by Khanuja et al in 2004–2005. [42

Mechanism of Action Of Bioenhancers
Bioavailability-enhancing activity of natural compounds from the medicinal plants may be attributed to various mechanisms, such as P-gp inhibition activity by flavone, quercetin, and genistein; [51] inhibition of efflux transporters, such as P-gp and breast cancer resistance protein (BCRP),[52,53] by naringin and sinomenine thus preventing drug resistance; DNA receptor binding, modulation of cell signaling transduction, and inhibition of drug efflux pumps[54-56] ; by stimulating leucine amino peptidase and glycyl–glycine dipeptidase activity, thus modulating the cell membrane dynamics related to passive transport mechanism as seen with piperine [57] ; nonspecific mechanisms, such as increased blood supply to the gastrointestinal tract, decreased hydrochloric acid secretion, preventing breakdown of some drugs[6] ; and inhibition of metabolic enzymes participating in the biotransformation of drugs, thus preventing inactivation and elimination of drugs and thereby, increasing their bioavailability. [57-5]


Scientific Papers found: Click to Expand⟱
7714- IP6,  ACNs,    Enhanced absorption of anthocyanins after oral administration of phytic acid in rats and humans
- in-vivo, Nor, NA
*BioEnh↑, *BioAv↑, *Dose↝,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Total Targets: 0

Pathway results for Effect on Normal Cells:


Drug Metabolism & Resistance(tgid=21)

BioAv↑, 1,   BioEnh↑, 1,   Dose↝, 1,  
Total Targets: 3

Scientific Paper Hit Count for: BioEnh, bioenhancer
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:103  Target#:1310  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page